5th Circuit Affirms That Abilify Tardive Dyskinesia Claim Is Prescribed By State Law
NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals on May 17 affirmed a district court’s finding that a plaintiff's neurological injury claim involving the atypical antipsychotic drug Abilify was...To view the full article, register now.
Already a subscriber? Click here to view full article